Facebook
Twitter
LinkedIn
Forward
CAR Therapy
Welcome!
We are delighted that you have chosen the Therapeutic Modalities module to start or enhance your current educational journey in immuno-safety science. This lecture is one in a series of five providing detailed information on current and/or emerging therapeutics that interact with the immune system. Please review the learning objectives below for more information on what you will learn in this lecture.
If you are new to HESI and would like to learn more about our organization, please take a moment to visit our website at https://hesiglobal.org/.
Target Audience
This course is intended for the science professional or graduate student looking to learn the fundamental science and key consideration that are examined in immune safety assessment. Advanced topics and coursed that take a deeper dive into specific scientific areas will be offered and are recommended for the more experienced scientist who has a firm grasp of the information highlighted in the introduction module.
Learning Objectives
The learner will be able to:
- Describe the fundamental concepts of how a CAR T cell works.
- Understand the basic nonclinical assessments of CAR T therapy in support of clinical development.
- Understand considerations applied for clinical trial design of cell therapies.
- Recognize the gaps and needs for future CAR T development in the field of Oncology.
Additional Information
| Attachment | Size |
|---|---|
 CAR Therapy slide deck - Abikoff Gauthier | 3.48 MB |
Lectures in this module
CAR Therapy
Safety Considerations for Oligonucleotides
CD3-binding (T cell engaging) immune stimulating antibody-based therapies
Gene Therapy
Nonclinical Development of Biologics
Cori Abikoff, MD
Senior Medical Director, Cell Therapy Clinical Research
Takeda Pharmaceuticals International Co.
Lauren Gauthier, MS, PhD
Scientific Director, Drug Safety Therapeutic Area Lead of Oncology and Cell Therapy
Takeda Pharmaceuticals International Co.
Scientific Director, Drug Safety Therapeutic Area Lead of Oncology and Cell Therapy
Takeda Pharmaceuticals International Co.
Available Credit
- 0.50 Participation
Price
Cost:
$25.00
Required Hardware/software
This platform, Ethos CE, works with most modern web browsers (e.g., Chrome, Internet Explorer, MS Edge, Safari). Contact itc@hesiglobal.org if you are having any difficulties with this platform.